Pfizer Inc. $PFE Shares Sold by Ingalls & Snyder LLC

Ingalls & Snyder LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 2.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 734,811 shares of the biopharmaceutical company’s stock after selling 20,502 shares during the quarter. Ingalls & Snyder LLC’s holdings in Pfizer were worth $18,723,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Curio Wealth LLC lifted its stake in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the last quarter. Grey Fox Wealth Advisors LLC purchased a new stake in Pfizer in the 3rd quarter valued at about $29,000. Howard Hughes Medical Institute acquired a new position in Pfizer in the second quarter valued at about $30,000. Darwin Wealth Management LLC purchased a new position in Pfizer during the second quarter worth about $32,000. Finally, Evelyn Partners Asset Management Ltd purchased a new position in Pfizer during the second quarter worth about $33,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on PFE shares. Bank of America decreased their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a research note on Thursday, February 12th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Wolfe Research set a $24.00 price objective on Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Finally, UBS Group assumed coverage on Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $28.00.

Pfizer Stock Down 0.8%

Shares of NYSE PFE opened at $27.37 on Wednesday. The stock has a market cap of $155.62 billion, a P/E ratio of 20.13 and a beta of 0.47. The business’s fifty day simple moving average is $25.88 and its 200-day simple moving average is $25.26. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.94. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.Pfizer’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.3%. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.